Agios Pharmaceuticals, Inc. (AGIO)
33.10
-0.03
(-0.09%)
USD |
NASDAQ |
Sep 04, 16:00
33.08
-0.02
(-0.06%)
Pre-Market: 20:00
Agios Pharmaceuticals Research and Development Expense (Quarterly) : 99.40M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 99.40M |
| March 31, 2026 | 79.78M |
| December 31, 2025 | 86.79M |
| September 30, 2025 | 85.42M |
| June 30, 2025 | 90.68M |
| March 31, 2025 | 71.46M |
| December 31, 2024 | 81.44M |
| September 30, 2024 | 71.11M |
| June 30, 2024 | 75.81M |
| March 31, 2024 | 67.27M |
| December 31, 2023 | 76.09M |
| September 30, 2023 | 80.22M |
| June 30, 2023 | 67.09M |
| March 31, 2023 | 65.51M |
| December 31, 2022 | 68.48M |
| September 30, 2022 | 62.98M |
| June 30, 2022 | 72.23M |
| March 31, 2022 | 67.64M |
| December 31, 2021 | 71.10M |
| September 30, 2021 | 61.79M |
| June 30, 2021 | 59.66M |
| March 31, 2021 | 55.19M |
| December 31, 2020 | 56.84M |
| September 30, 2020 | 49.63M |
| June 30, 2020 | 51.67M |
| Date | Value |
|---|---|
| March 31, 2020 | 52.88M |
| December 31, 2019 | 104.28M |
| September 30, 2019 | 101.67M |
| June 30, 2019 | 107.39M |
| March 31, 2019 | 95.58M |
| December 31, 2018 | 93.81M |
| September 30, 2018 | 82.56M |
| June 30, 2018 | 86.73M |
| March 31, 2018 | 78.22M |
| December 31, 2017 | 77.22M |
| September 30, 2017 | 72.92M |
| June 30, 2017 | 79.82M |
| March 31, 2017 | 62.73M |
| December 31, 2016 | 64.68M |
| September 30, 2016 | 60.64M |
| June 30, 2016 | 50.80M |
| March 31, 2016 | 44.04M |
| December 31, 2015 | 36.93M |
| September 30, 2015 | 36.03M |
| June 30, 2015 | 36.42M |
| March 31, 2015 | 32.44M |
| December 31, 2014 | 34.86M |
| September 30, 2014 | 25.53M |
| June 30, 2014 | 22.25M |
| March 31, 2014 | 17.41M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Biogen, Inc. | 461.70M |
| Insmed, Inc. | 210.03M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Regeneron Pharmaceuticals, Inc. | 1.508B |